Research Paper Volume 13, Issue 14 pp 18545—18563
The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation
Figure 2. Fraxetin inhibits PCC invasion and migration by regulating the Slug-E-cadherin axis. (A) Transwell chamber assays were used to investigate the effects of fraxetin on the invasion number of PANC-1 and Patu8988 cells. (B) A wound healing assay was used to determine the effects of fraxetin on the migration rate of PANC-1 and Patu8988 cells. (C) N-cadherin, Vimentin, E-cadherin, and Slug expression in fraxetin-treated PANC-1 and Patu8988 cells as shown on Western blot. (D) Immunocytochemical staining of E-cadherin and α-SMA in fraxetin-treated PANC-1 and Patu8988 cells. Bar = 25 μm. Data were presented as the mean ± standard deviation and were analyzed by One-way ANOVA with Bonferroni’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001.